



MEDICAGO NAMED EARLY STAGE COMPANY OF THE YEAR BY BIOTECCanada

-Company to receive Gold Leaf Award at BIO 2009-

Quebec City, Quebec— May 13, 2009 — Medicago Inc. (TSX-V: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has been selected to receive the Gold Leaf Award from BIOTECCanada for “Early Stage Company of the Year”. Medicago will be presented with this distinguished award on May 19, 2009 at the 2009 BIO International Convention in Atlanta, USA. The award is given annually to a company that has distinguished itself from its peers with demonstrated technology innovation milestone achievements and financial success.

“This leading firm is a stellar example of Canadian innovative thinking, partnership potential, and research and development expertise,” said BIOTECCanada President and CEO, Peter Brenders. “Once commercialized, its products will make a significant contribution to Canada’s economy.”

“We are honoured to have received this prestigious award from BIOTECCanada,” said Andy Sheldon, President and CEO of Medicago. “We are at an important stage of development with our first VLP vaccine entering Phase I clinical trials later this year. This award recognizes the outstanding contribution that Medicago’s employees have made to the development of our technology and achievement of corporate objectives.”

About Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This press release contains forward-looking statements which reflect Medicago's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any obligation to update these forward-looking statements.

- 30 -

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Contact:

Medicago, Inc.
Andy Sheldon
President and CEO
(418) 658-9393

Medicago Inc.
Arianna Vanin
Director, Investor Relations
(514) 796-3993